AZD0486, A NOVEL CD19XCD3 T-CELL ENGAGER, SHOWS DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATE ON EFFICACY AND SAFETY

EHA Library, Sumana Devata, 419218

PATIENT CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL) IN THE UNITED STATES (US), CANADA, AND EUROPE: A PANEL-BASED CHART REVIEW STUDY

EHA Library, Craig Portell, 419221

SAFETY AND PRELIMINARY EFFICACY OF BI-1206, AN ANTIBODY TO CD32B (FCGRIIB), GIVEN IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Mariana Beatriz Bastos, 419222

EPIDEMIOLOGICAL FEATURES AND PROGNOSIS FOR PRIMARY GASTROINTESTINAL FOLLICULAR LYMPHOMA

EHA Library, Huilai Zhang, 419223

PRELIMINARY SAFETY AND EFFICACY OF BOVEN (ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX) FOR FRONTLINE THERAPY FOR OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Anita Kumar, 419225

REAL-WORLD COMPARATIVE EFFECTIVENESS OF COVALENT BRUTON TYROSINE KINASE INHIBITORS (CBTKI) AMONG PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)

EHA Library, Tycel Phillips, 419226

THE EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS STANDARD OF CARE (SCHOLAR-5) IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES: AN INDIRECT TREATMENT COMPARISON

EHA Library, Anna Sureda Balari, 419227

INTRAPATIENT COMPARATIVE ANALYSIS OF ZANUBRUTINIB PLUS OBINUTUZUMAB EFFICACY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA USING THE GROWTH MODULATION INDEX

EHA Library, Kamal Bouabdallah, 419230

INCIDENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA: A SINGLE CENTRE REAL-WORLD EXPERIENCE

EHA Library, Nicole Japzon, 419231

CLINICAL EFFICACY OF RUXOLITINIB IN T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA VIA A NON-TUMOR CELL AUTONOMOUS MECHANISM

EHA Library, Amira Marouf, 419234

FRONTLINE TREATMENT WITH ZANUBRUTINIB PLUS RITUXIMAB (ZR) FOLLOWED BY SHORT COURSE R-DHAOX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) – RESULTS OF PHASE II CHESS TRIAL

EHA Library, Qingqing Cai, 419235

A COMPARISON OF TREATMENT OUTCOMES BETWEEN CYCLOSPORIN AND CHEMOTHERAPY IN SUBCUTANEOUS PANNICULITIS-LIKE T-CELL LYMPHOMA (SPTCL): REPORT FROM THE NATIONWIDE MULTI-CENTER THAI LYMPHOMA STUDY GROUP

EHA Library, Thitirat Tirachotikul, 419237

EPCORITAMAB + GEMOX INDUCES DEEP, DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM THE EPCORE NHL-2 TRIAL

EHA Library, Raul Cordoba, 419239

OUTCOMES IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH TAFASITAMAB PLUS LENALIDOMIDE POST-CD19-TARGETING CAR-T THERAPY: A LYSA STUDY FROM THE DESCAR-T REGISTRY

EHA Library, Vincent Camus, 419240

PREVALENCE OF CARDIOVASCULAR RISK FACTORS AND LEFT VENTRICULAR DYSFUNCTION IN SURVIVORS OF DIFFUSE LARGE B-CELL LYMPHOMA COMPARED WITH SIBLING CONTROLS

EHA Library, Suzanne Neppelenbroek, 419242

SECONDARY PRIMARY MALIGNANCIES AFTER CD19-DIRECTED CAR-T CELL THERAPY IN LYMPHOMAS: A REPORT FROM THE ITALIAN CART-SIE STUDY

EHA Library, Angelica Barone, 419243

BRIGATINIB MONOTHERAPY IN CHILDREN WITH R/R ALK+ ALCL: PRELIMINARY RESULTS FROM THE BRIGAPED (ITCC-098) PHASE 1 DOSE-ESCALATION STUDY

EHA Library, Charlotte Rigaud, 419245

A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY WITH A PD-1 KNOCKOUT (CB-010) FOR RELAPSED/REFRACTORY B CELL NON-HODGKIN LYMPHOMA (R/R B-NHL): UPDATED PHASE 1 RESULTS FROM THE ANTLER TRIAL

EHA Library, Boyu Hu, 419247

SUPERIOR EFFECTS OF CD19/20 DUAL-TARGETING CAR-T IN PATIENTS WITH RELAPSED/REFRACTIVE B-CELL LYMPHOMA: A MULTICENTER PRELIMINARY INTERIM REPORT

EHA Library, Jiaqi Guo, 419251

GENOMIC PROFILING IN A SUBGROUP ANALYSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND EXTRANODAL (EN) SITES OF INVOLVEMENT IN THE PHASE III POLA-R-CHP VERSUS R-CHOP (POLARIX) STUDY

EHA Library, Gilles Salles, 419256

PHASE 2 STUDY OF ANTI-PD-L1 ANTIBODY ATEZOLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA: NCCH1903/ATTACK STUDY

EHA Library, Shinichi Makita, 419257

ANALYSIS OF CCND3 MUTATIONS IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 419261

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD) - FINNISH REAL-LIFE DATA WITH LONG-TERM FOLLOW-UP ON 215 SOLID ORGAN RECIPIENTS

EHA Library, Terhi Friman, 419263

THE PROGNOSTIC SIGNIFICANCE OF MYC/BCL2 DOUBLE EXPRESSION IN DIFFUSE LARGE B CELL LYMPHOMA IN THE GENETIC CLASSIFICATION ERA

EHA Library, Jin-Hua Liang, 419264

REAL-WORLD EXPERIENCE OF POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB AND BENDAMUSTINE IN RELAPSED AND REFRACTORY LARGE B-CELL LYMPHOMAS.

EHA Library, Michał Danecki, 419269

PREDICTING THE TRULY LOW-RISK PATIENTS WITH TNFRSF14 MUTATION USING MACHINE LEARNING ALGORITHMS IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Jin-Hua Liang, 419270

A VISUAL NOMOGRAM SURVIVAL PREDICTION MODEL IN ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)-RELATED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, chongling Hu, 419271

SIGNIFICANT OUTCOME IMPROVEMENT OF THE ENTIRE R/R DLBCL POPULATION RECEIVING THIRD LINE THERAPY IN THE CAR T-CELL ERA

EHA Library, Marek Trneny, 419273

CD22-TARGETED CAR T CELL SINGLE CELL MULTIOMIC FEATURES LINKED TO PATIENT OUTCOMES IN CD19-CAR RESISTANT LARGE B CELL LYMPHOMA

EHA Library, Anne Marijn Kramer, 419276

TUMOR MUTATIONS AND IMMUNOHISTOCHEMICAL TUMOR EXPRESSION IMPACTS SURVIVAL IN PATIENTS WITH B CELL LYMPHOMA TREATED WITH BISPECIFIC CD20XCD3 ANTIBODIES

EHA Library, Emil Kyvsgaard, 419277

CAR-T CELL THERAPY SHOWS SIMILAR EFFICACY AND TOXICITY IN PATIENTS WITH DLBCL AGED 70 AND OLDER COMPARED TO YOUNGER PATIENTS: A MULTICENTER COHORT STUDY

EHA Library, Philipp Berning, 419279

THE PRIMARY RESULTS OF R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) AS THE FIRST-LINE INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Zengjun Li, 419280

PHASE IB/II STUDY OF RITUXIMAB, LENALIDOMIDE, AND METHOTREXATE FOLLOWED BY LENALIDOMIDE MAINTENANCE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA: THE REMLA TRIAL

EHA Library, Yan Zhang, 419282

DECREASES IN LEFT VENTRICULAR FUNCTION IN ELDERLY PATIENTS WITH LARGE B-CELL LYMPHOMA RECEIVING CHOP REGIMENS IN THE RICOVER-60 TRIAL: RISK FACTORS AND OUTCOMES

EHA Library, Igor Age Kos, 419284

REAL-WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR TREATMENT OF RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA IN CANADA

EHA Library, Christopher Lemieux, 419286

ANATOMICAL PATTERN OF CNS RELAPSE IN AGGRESSIVE B-CELL LYMPHOMAS

EHA Library, Izel Okcu, 419287

CLINICAL CHARACTERISTICS, TREATMENTS, AND OUTCOMES OF LARGE B-CELL LYMPHOMA PATIENTS IN THIRD-LINE THERAPY INCLUDED BETWEEN 2018 AND 2023 IN THE FRENCH PROSPECTIVE MULTICENTRIC REALYSA COHORT

EHA Library, Caterina Cristinelli, 419288

EARLY PET EVALUATION AT DAY 14 POST AXICABTAGENE CILOLEUCEL INFUSION PREDICTS OUTCOME IN LARGE B-CELL LYMPHOMA: RESULTS FROM THE ALYCANTE PHASE II STUDY

EHA Library, Yassine Al Tabaa, 419289

ANALYSIS OF LARGE B-CELL LYMPHOMA PATIENTS FAILED AFTER CAR T-CELL THERAPY: SEVERAL FACTORS PREDICTING OUTCOME OF RELAPSED/PROGRESSED PATIENTS ARE ALREADY PRESENT BEFORE CELL INFUSION

EHA Library, Robert Pytlík, 419294

CLINICAL CHARACTERISTICS, TREATMENT OPTIONS AND OUTCOME OF REFRACTORY AND EARLY RELAPSE LARGE B CELL LYMPHOMA (LBCL) PATIENTS INCLUDED IN THE REALYSA COHORT BEFORE CAR T CELLS ERA.

EHA Library, Stephanie Guidez, 419295

PATIENT CHARACTERISTICS, BURDEN OF DISEASE AND HEALTHCARE UTILIZATION IN DIFFUSE LARGE B-CELL LYMPHOMA – AN ANALYSIS OF GERMAN CLAIMS DATA

EHA Library, Moritz Lehne, 419297

COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSES OF AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY IN PATIENTS WITH LARGE B-CELL LYMPHOMA IN SINGAPORE

EHA Library, Francesca Lim, 419304

THE PHASE II STUDY OF ZANUBRUTINIB COMBINED WITH R-CHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH SPECIFIC GENE-EXPRESSION

EHA Library, Qunling Zhang, 419305

INTELLIGENT INTEGRATION: DEEP LEARNING ENSEMBLE CLASSIFIER FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, GLIOMA, AND BRAIN METASTASIS - A RETROSPECTIVE STUDY

EHA Library, Bihui Pan, 419307

MONOMORPHIC LYMPHOPROLIFERATIVE DISORDERS FOLLOWING HEART TRANSPLANTATION: A SINGLE CENTER EXPERIENCE ON 1055 TRANSPLANTS.

EHA Library, Anna Maria Barbui, 419308

CD58 GENETIC ALTERATIONS GOVERN ANTITUMOR IMMUNE RESPONSES BY REGULATING PD-L1 AND IDO VIA THE LYN/CD22/SHP1 AXIS IN DLBCL

EHA Library, Xiyue Xu, 419313

SPECIFIC IMMUNE-MOLECULAR PROFILES DISTINGUISH TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA FROM NODAL-DLBCL-ABC

EHA Library, Ruben de Groen, 419315

PD-1 AND TIGIT IMMUNE-CHECKPOINT BLOCKADE IN NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA

EHA Library, Maher Gandhi, 419316

UNRAVELING THE MECHANISMS OF BCL7A-MEDIATED TUMOR SUPPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA: A MULTI-OMIC APPROACH

EHA Library, Fernando Montenegro Elvira, 419318

SAFETY AND EFFICACY OF GOLCADOMIDE, A POTENTIAL FIRST-IN-CLASS CELMOD AGENT ± RITUXIMAB IN A PHASE 1/2 OPEN-LABEL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

EHA Library, Julio Chavez, 419219

COMPARATIVE EFFECTIVENESS OF EPCORITAMAB VERSUS REAL-WORLD USUAL CARE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Tycel Phillips, 419220

UNDETECTABLE MEASURABLE RESIDUAL DISEASE (MRD) IS ASSOCIATED WITH IMPROVED LONG-TERM OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) TREATED WITH CHEMO-IMMUNOTHERAPY: RESULTS FROM SWOG S0016

EHA Library, Alexey Danilov, 419224

ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (MCL): UPDATED RESULTS OF THE MULTICENTER, PHASE II POLARIS STUDY

EHA Library, Huilai Zhang, 419228

CLINICAL FEATURES, TREATMENT PATTERNS, AND OUTCOMES OF DUODENAL-TYPE FOLLICULAR LYMPHOMA WITH A LONG-TERM FOLLOW-UP OBSERVATIONAL STUDY

EHA Library, Fuka Mima, 419229

ZANUBRUTINIB IN BING-NEEL SYNDROME: EFFICACY AND TOLERABILITY

EHA Library, Josephine Vos, 419232

EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) IN PREVIOUSLY UNTREATED (1L) FOLLICULAR LYMPHOMA (FL) AND EPCORITAMAB MAINTENANCE THERAPY IN FL: NOVEL RESULTS FROM EPCORE NHL‑2 ARMS 6 AND 7

EHA Library, Lorenzo Falchi, 419233

EZH2 ABERRATIONS IN ADVANCED FOLLICULAR LYMPHOMA: FIRST TRANSLATIONAL RESULTS OF FOLL-EZ, AN ANCILLARY STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL

EHA Library, Simone Ferrero, 419236

EXTENDED FOLLOW-UP BEYOND 2.5 YEARS SHOWS LONG-TERM EFFICACY IN COMPLETE RESPONDERS FOLLOWING EPCORITAMAB MONOTHERAPY IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Catherine Thieblemont, 419238

DEFINITION AND USE OF BULKY DISEASE IN LYMPHOMA CARE: A STUDY FROM THE AUSTRALASIAN LYMPHOMA AND RELATED DISEASES REGISTRY (LARDR)

EHA Library, Eliza Chung, 419241

FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS (PTS) WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: RESULTS FROM THE PHASE 2 SGN35-032 STUDY

EHA Library, Swaminathan Iyer, 419244

ZUMA-24 PRELIMINARY ANALYSIS: A PHASE 2 STUDY OF AXICABTAGENE CILOLEUCEL IN THE OUTPATIENT SETTING WITH PROPHYLACTIC CORTICOSTEROIDS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Lori Leslie, 419246

EPCORITAMAB + R-DHAX/C ELICITS DEEP, DURABLE RESPONSES IN TRANSPLANT-ELIGIBLE PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING HIGH-RISK DISEASE

EHA Library, Pau Abrisqueta, 419248

ODRONEXTAMAB DEMONSTRATES DURABLE COMPLETE RESPONSES IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PROGRESSING AFTER CAR-T THERAPY: OUTCOMES FROM THE ELM-1 STUDY

EHA Library, Jean-Marie Michot, 419249

PLASMA CELL-FREE DNA AS AN ALTERNATIVE TO TISSUE DNA FOR DETECTING GENETIC ALTERATIONS OF IVLBCL

EHA Library, Chao Chen, 419250

ANBALCABTAGENE AUTOLEUCEL (PD-1 AND TIGIT KNOCK-DOWNED CD19 CAR-T) FOR RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS: RESULT OF A PIVOTAL PHASE 2 STUDY.

EHA Library, Won-Seog Kim, 419252

REAL-WORLD ANALYSIS OF GLOFITAMAB FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN GERMANY, AUSTRIA AND SWITZERLAND

EHA Library, Rebecca WURM-KUCZERA, 419253

ORIENT STUDY: ORELABRUTINIB ADDITION TO R-CHOP-LIKE REGIMEN ADAPTED TO RESPONSE IN TREATMENT-NAÏVE NON-GCB DLBCL

EHA Library, Chang-Ju Qu, 419254

PHASE I-II STUDY COMBINING BRENTUXIMAB VEDOTIN WITH R-DHAP AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN CD30 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: RESULTS OF THE HOVON 136 STUDY

EHA Library, Pieternella (Elly) Lugtenburg, 419255

COMPARISON OF ZUBERITAMAB PLUS CHOP WITH RITUXIMAB PLUS CHOP FOR THE TREATMENT OF DRUG-NAÏVE PATIENTS DIAGNOSED WITH CD20-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE 3 TRIAL

EHA Library, Zhi-Ming Li, 419258

VALEMETOSTAT MONOTHERAPY IN RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS: A FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL

EHA Library, Dai Maruyama, 419259

FEASABILITY AND SAFETY DATA OF THE CHEMOTHERAPY-LIGHT COMBINATION OF RITUXIMAB, POLATUZUMAB VEDOTIN AND GLOFITAMAB IN AGGRESSIVE B-CELL LYMPHOMA PATIENTS INELIGIBLE FOR FULLY DOSED R-CHOP

EHA Library, Rebecca WURM-KUCZERA, 419260

ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOLLOWED BY ZANUBRUTINIB MAINTENANCE FOR PRIMARY VITREORETINAL LYMPHOMA: A PROSPECTIVE PROOF-OF-CONCEPT PHASE II STUDY

EHA Library, Yan Zhang, 419262

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMAS– UPDATED ANALYSIS OF REAL-WORLD DATA

EHA Library, Magdalena Klanova, 419265

FRONTLINE TREATMENT CHOICES AND GENETIC CHARACTERISTICS OF PATIENTS WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA WITH SYNCHRONOUS CNS AND SYSTEMIC INVOLVEMENT.

EHA Library, Jacopo Calabrese De Feo, 419267

CD19/BCMA DUAL-TARGETING FASTCAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA: AN UPDATE

EHA Library, Xinfeng Chen, 419268

ZANUBRUTINIB, LENALIDOMIDE, RITUXIMAB, TEMOZOLOMIDE AND METHOTREXATE (RLZT±MTX) AS FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED PCNSL: A PROSPECTIVE, OPEN-LABEL, MULTICENTER CLINICAL TRIAL

EHA Library, Jia Song, 419272

EXPLORATION OF THE OPTIMAL TREATMENT MODALITY FOR VITREORETINAL LYMPHOMA: A PRISMA COMPLIANT META-ANALYSIS AND SYSTEMATIC REVIEW

EHA Library, Liang Wang, 419274

BASELINE PET TOTAL METABOLIC TUMOR VOLUME HAS A PROGNOSTIC ROLE IN PTCLS – DATA FROM INTERNATIONAL PROSPECTIVE T-CELL PROJECT 2.0

EHA Library, Tetiana Skrypets, 419275

UPDATED TRENDS IN REAL-WORLD OUTPATIENT (OP) ADMINISTRATION OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)

EHA Library, Radhika Bansal, 419278

ORELABRUTINIB IN COMBINATION WITH PD-1 INHIBITOR IN REFRACTORY OR RELAPSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 419281

IMPACT OF CD19 EXPRESSION BY IMMUNOHISTOCHEMISTRY IN LYMPHOMA PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL

EHA Library, Marcos Rivada, 419283

NIVOLUMAB CONSOLIDATION AFTER DA-EPOCH-R INDUCTION INDUCES HIGH RATES OF DISEASE-FREE AND OVERALL SURVIVAL IN PATIENTS WITH DOUBLE AND TRIPLE HIT HIGH-GRADE B-CELL LYMPHOMA

EHA Library, Martine Chamuleau, 419285

TAFASITAMAB PLUS LENALIDOMIDE AS SALVAGE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: THE SPANISH GROUP OF LYMPHOMA (GELTAMO) REAL-WORLD EXPERIENCE.

EHA Library, Antonio Gutiérrez, 419290

REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH TREATMENT-NAÏVE AND RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES

EHA Library, Jennifer Lue, 419291

COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB IN RELAPSED/REFRACTORY NHL AND MM: AN ANALYSIS OF COHORTS C TO F OF THE PHASE 2 KEYVIBE-004 STUDY

EHA Library, Sylvain Choquet, 419292

INITIAL RESULTS FROM THE PRIZM+ PHASE II PLATFORM STUDY FOR RELAPSED AND REFRACTORY PRIMARY CNS LYMPHOMA:  COHORT 1 ZANUBRUTINIB MONOTHERAPY

EHA Library, Christopher Fox, 419293

SINTILIMAB PLUS GEMOX IS AN EFFECTIVE SALVAGE THERAPY IN PATIENTS WITH REFRACTORY⁄RELAPSING NODAL PERIPHERAL T CELL LYMPHOMAS

EHA Library, Xibin Xiao, 419296

DIAGNOSTIC AND PROGNOSTIC IMPACTS OF RHOA G17V MUTATION IN CELL-FREE DNA ASSESSED BY DROPLET DIGITAL POLYMERASE CHAIN REACTION IN PATIENTS WITH ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

EHA Library, Yi Miao, 419298

WAVELINE-004: UPDATED RESULTS FROM THE PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (ZV) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Muhit Ozcan, 419299

ENHANCED EFFICACY AND SAFETY FROM PHASE 2 STUDY OF IMC-001, ANTI-PD-L1 ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA (R/R ENKTL), NASAL TYPE: DISTINKT STUDY

EHA Library, Won Seog Kim, 419300

EARLYMIND, A RETROSPECTIVE MULTICENTER STUDY IN REAL-WORLD SETTINGS TO CHARACTERIZE TAFASITAMAB-LENALIDOMIDE EFFICACY IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Charles Herbaux, 419301

PROGNOSTICATION IN SECONDARY CNS LYMPHOMA PATIENTS TREATED WITH MATRIX OR AN ALTERNATIVE (KORFEL ET AL. NCT01148173) INDUCTION REGIMEN AND AUTOLOGOUS STEM CELL TRANSPLANTATION CONSOLIDATION

EHA Library, Fleur de Groot, 419302

OUTCOMES OF ANTHRACYCLINE-BASED CHEMOIMMUNOTHERAPY IN DE NOVO AND TRANSFORMED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Maximilian Seib, 419303

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE AFTER 5797 SOLID-ORGAN TRANSPLANTS OVER A 30-YEAR PERIOD IN A SINGLE HOSPITAL.

EHA Library, Ana Jiménez Ubieto, 419306

A MULTI-CENTER, OPEN-LABEL, PHASE 1/2 STUDY OF ONCT-808, A ROR1-TARGETING CAR-T CELL THERAPY, IN ADULTS WITH RELAPSED/REFRACTORY (R/R) AGGRESSIVE B CELL LYMPHOMAS (BCL)

EHA Library, Michael L. Wang, 419309

POLATUZUMAB VEDOTIN-INDUCED INNATE IMMUNE CELL INFILTRATION CONTRIBUTES TO ITS ANTITUMOR EFFECT IN A HUMAN DLBCL XENOGRAFT MODEL

EHA Library, Mayu Tomita, 419310

IMPACT OF BCR-IGH DIVERSITY ON PROGNOSIS IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Takahiro Haeno, 419311

MUTANT STAT5B TRIGGERS NK-CELL NEOPLASMS

EHA Library, Dagmar GOTTHARDT, 419312

INTEGRATION OF [18F]FDG-PET RADIOMICS WITH LIQUID BIOPSY IMPROVES OUTCOME PREDICTION IN NEWLY DIAGNOSED DLBCL PATIENTS

EHA Library, Riccardo Dondolin, 419314

CIRCULATING TUMOR DNA ANALYSIS ASSOCIATES WITH PFS WITH ODRONEXTAMAB MONOTHERAPY IN R/R FL AND DLBCL: IDENTIFICATION OF MRD STATUS AND HIGH-RISK SUBGROUPS FROM THE PHASE 2 ELM-2 STUDY

EHA Library, David Tucker, 419317